{"id":"vehicle-of-adx-102-ophthalmic-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADX-102 is a reactive oxygen species (ROS) scavenger that reduces oxidative stress in ocular tissues. The vehicle formulation optimizes drug delivery, stability, and tolerability of ADX-102 when administered as ophthalmic drops to the eye.","oneSentence":"This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:26.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT04674358","phase":"PHASE2, PHASE3","title":"The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2020-11-21","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":329},{"nctId":"NCT03709121","phase":"PHASE1, PHASE2","title":"A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-10-02","conditions":"Conjunctivitis, Allergic","enrollment":70},{"nctId":"NCT03131154","phase":"PHASE3","title":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2017-04-26","conditions":"Non-infectious Anterior Uveitis","enrollment":123},{"nctId":"NCT05424549","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2022-03-09","conditions":"Dry Eye Syndromes","enrollment":63},{"nctId":"NCT04207736","phase":"PHASE3","title":"The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-12-05","conditions":"Allergic Conjunctivitis","enrollment":95},{"nctId":"NCT03012165","phase":"PHASE2","title":"A Study of ADX-102 in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2016-12","conditions":"Conjunctivitis, Allergic","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle of Reproxlap"],"phase":"phase_3","status":"active","brandName":"Vehicle of ADX-102 Ophthalmic Drops","genericName":"Vehicle of ADX-102 Ophthalmic Drops","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface. Used for Dry eye disease, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}